|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 1 Baseline characteristics of included studies in patients with T2DM and CKD | Duration of diabetes | C |  | 16.6±8.8 | 14.5±8.5 | N/A |  | N/A | 15.7±8.2 | 14.5±8.9 | 16.0±8.6 | N/A | 13.8 | N/A | 20.7±8.9 |  | 14.9±8.5 | N/A | N/A | N/A | N/A | N/A | Note: I: intervention; C: control; N/A: not available |
| I |  | 16.6±8.8 |  | 16.1±8.4 | 15.5±8.7 | 13.7 | 200mg:19.6±9.3 400mg:18.5±9.2 |  | 15.4±8.7 |
| eGFR (ml/min/1.73 m2) | C |  | 44.3±12.6 | 67.8±21.7 | 72.2±20.4 |  | 48.6±7.8 | 49.0±8.3 | 51.4±7.2 | 56.0±18.3 | N/A | 43.6±12.6 | 44.7 | 24.1±4.4 |  | 45.8±10.8 | N/A | N/A | 49.2 | N/A | N/A |
| I |  | 44.4±12.5 | 1.25mg: 66.1±21.9 2.5mg: 67.4±20.2 5mg: 67.1±22.2 7.5mg: 67.5±21.9 10mg: 67.0±20.9 15mg: 67.5±23.6 20mg: 66.0±22.2 |  | 48.4±8.2 | 49.2±7.8 | 56.3±18.2 | 44.0±12.6 | 44.4 | 200mg:23.8±4.8 400mg:23.9±4.4 |  | 45.5±10.9 |
| HbA1C (%) | C |  | 7.7±1.4 | 7.7±1.4 | 7.6±1.3 |  | 8.03±0.85 | 8.3±0.9 | 8.2±1.2 | 8.3±1.3 | N/A | 7.8±1.6 | 8.3 | 8.4±1.1 |  | 8.6±1.5 | N/A | N/A | 8.1 | N/A | N/A |
| I |  | 7.7±1.3 | 1.25mg: 7.6±1.3 2.5mg: 7.6±1.3 5mg: 7.5±1.3 7.5mg:7.5±1.2 10mg: 7.7±1.2 15mg: 7.5±1.2 20mg: 7.7±1.3 |  | 8.07±0.86 | 8.3±1.0 | 8.3±1.3 | 7.8±1.7 | 8.3 | 200mg:8.3±1.0 400mg:8.3±0.9 |  | 8.7±1.6 |
| BMI | C |  | N/A | 31.4±6.0 | 32.49±5.27 |  | 30.9±5.4 | 32.5±6.2 | 34.5±6.0 | 31.3±6.2 | N/A | 30.4±6.3 | 31.7 | 31.7±5.7 |  | 32.7±6.6 | N/A | N/A | 32.8 | N/A | N/A |
| I |  | 1.25mg: 32.19±6.67 2.5mg: 31.54±5.42 5mg: 31.85±5.44 7.5mg: 31.60±5.81 10mg: 31.70±5.39 15mg: 31.97±5.66 20mg: 31.39±4.72 |  | 31.0±5.5 | 32.1±5.9 | 31.4±6.2 | 30.2±6.2 | 31.9 | 200mg:30.9±5.4 400mg:32.1±6.2 |  | 32.6±6.4 |
| Male | C |  | 2030 | 5107 | 69 |  | 418 | 527 | 814 | 1467 | N/A | 980 | 2885 | 42 |  | 631 | N/A | N/A | 1815 | N/A | N/A |
| I |  | 1953 | 570 |  | 816 | 659 | 1440 | 961 | 2945 | 93 |  | 691 |
| Age | C |  | 65.7±9.2 | 64.1±9.8 | 63.26±8.68 |  | 67.1±8.2 | 67.6±7.6 | 67.3±6.6 | 63.2±9.2 | N/A | 64.7±9.5 | 69 | 68.0±8.3 |  | 67.3±7.5 | N/A | N/A | 66.5 | N/A | N/A |
| I |  | 65.4±8.9 | 1.25mg: 64.91±9.57 2.5mg: 64.89±9.09 5mg: 63.31±8.97 7.5mg: 63.73±10.04 10mg: 64.94±9.62 15mg: 63.95±8.34 20mg: 64.70±9.26 |  | 67.1±7.6 | 67.6±7.8 | 62.9±9.2 | 64.1±9.8 | 69 | 200mg:66.8±10.0 400mg:67.3±9.6 |  | 67.3±7.5 |
| Number of patients | C |  | 3841 | 3666 | 94 |  | 607 | 929 | 659 | 2199 | 608 | 1451 | 5292 | 93 |  | 1042 | 1118 | 1124 | 1620 | 422 | 470 |
| I |  | 2833 | 3686 | 727 |  | 1212 | 1110 | 606 | 2202 | 1199 | 1455 | 5292 | 184 | GLP-1 RA vs placebo | 1116 | 1081 | 1098 | 1157 | 434 | 469 |
| Total | Finerenone vs placebo | 6674 | 7352 | 821 | SGLT2i vs placebo | 1819 | 2039 | 1265 | 4401 | 1807 | 2906 | 10584 | 277 | 2158 | 2199 | 2222 | 3177 | 856 | 939 |
| eGFR (ml/min/1.73 m2) | 25 to <75 | 25 to 90 | ≥30 | 30 to 59 | 30 to <60 | <60 | 30 to <90 | 30 to <60 | 25 to 75 | 25 to 60 | 15 to <30 | <60 | 15 to <60 | 30 to <60 | 30 to <60 | 30 to <60 | <60 |
| Trial | FIDELIO-DKD | FIGARO-DKD | ARTS-DN | EMPA-REG | CANVAS  | DECLARE–TIMI 58 | CREDENCE | VERTIS CV | DAPA-CKD | SCORED | Cherney 2021 | LEADER | REWIND | HARMONY | EXSCEL | PIONEER-6 | SUSTAIN-6 |